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Abstract: Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM)
is a neurologic disease that has been reported in young horses from a wide range of breeds.
The disease is inherited and associated with vitamin E deficiency during the first two years of life,
resulting in bilateral symmetric ataxia. A missense mutation (chr3:71,917,591 C > T) within adhesion
G protein-coupled receptor L3 (ADGRL3) was recently associated with risk for EDM in the Caspian
breed. In order to confirm these findings, genotyping of this missense mutation, along with the three
other associated single nucleotide polymorphisms (SNPs) in the genomic region, was carried out
on 31 postmortem-confirmed eNAD/EDM cases and 43 clinically phenotyped controls from various
breeds. No significant association was found between eNAD/EDM confirmed cases and genotype
at any of the four identified SNPs (P > 0.05), including the nonsynonymous variant (EquCab2.0
chr3:71,917,591; allelic P = 0.85). These findings suggest that the four SNPs, including the missense
variant in the ADGRL3 region, are not associated with risk for eNAD/EDM across multiple breeds
of horses.
Keywords: equine neuroaxonal dystrophy; horse; vitamin E
1. Introduction
Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM) is a
neurologic disease that has been reported in young horses from a wide range of breeds. Equine
degenerative myeloencephalopathy (EDM) is a more histologically advanced form of equine
neuroaxonal dystrophy (eNAD). Equine NAD/EDM has been associated with vitamin E deficiency
during the first two years of life [1], resulting in the development of bilaterally symmetric proprioceptive
ataxia [2,3]. Using immunohistochemistry, deficits in the ascending proprioceptive tracts of the spinal
cord to the originating cell bodies within the dorsal root ganglion (DRG) were traced [4]. It has been
hypothesized that eNAD/EDM has either an autosomal dominant or polygenic mode of inheritance [5–7].
However, an autosomal recessive inheritance pattern has also been proposed [8]. Diagnosis of
eNAD/EDM can only be confirmed by postmortem histological evaluation of the brainstem and spinal
cord [3]. Four single nucleotide polymorphisms (SNPs) were recently identified to be associated with
EDM in the Caspian horse breed [8]. These variants were within adhesion G protein-coupled receptor
L3 (ADGRL3) and the nonsynonymous variant was proposed to be associated with risk for EDM in
this breed [8]. Of the four SNPs, SNP 1 (EquCab2.0 chr3:71,768,217 T > A) is located within the 3′
untranslated region of ADGRL3, SNP 2 (EquCab2.0 chr3:71,770,084 T > C; synonymous) and SNP 4
(chr3:71,917,591 C > T; non-synonymous) are exonic, and SNP 3 (EquCab2.0 chr3:71,836,145 G > A;) is
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intronic. As the putative variant was identified using two related EDM-affected Caspian horses and
there was a lack of appropriate controls [8], we hypothesized that this previously reported ADGRL3
variant would not be associated with eNAD/EDM status across breeds.
2. Materials and Methods
A total of 74 horses, 31 eNAD/EDM cases and 43 controls, were used in this study. Affected horses
were selected based on their postmortem diagnosis by board-certified veterinary pathologists. Control
horses were all over the age of 6 months and either postmortem-confirmed (n = 13) as unaffected
or known to be vitamin E-deficient during the first few years of life, though they demonstrated no
neurologic abnormalities when examined as adults (n = 30). The affected cohort included 14 Quarter
Horses, four Warmbloods, two Andalusians, two Thoroughbreds, two Dutch Warmbloods, two
Lusitanos, and one each of Paint, Morgan, Fell Pony, Thoroughbred/Quarter Horse Cross, and Arabian.
The unaffected cohort included 21 Quarter Horses, seven Warmbloods, five Thoroughbreds, two
Lusitanos, two Paints, and one each of Morgan, Thoroughbred/Quarter Horse Cross, Arabian, Percheron,
Friesian, and Pony of America. The disease status, ages, sexes, breeds, and genotypes of these horses
can be found in Supplementary Table S1. The cases had an average age of 2.8 years, while the average
age of the control horses was 9.6 years.
From each horse, a sample of genomic DNA was isolated from blood or tissue using the Promega
Wizard gDNA kit (Promega, Madison, WI, USA) or Gentra Puregene kit (Qiagen, Germantown, MD,
USA). Primer3Plus [9] was used to design four primer sets to amplify the regions containing one of
the four SNPs of interest (EquCab2.0; chr3:71,768,217 T > A, chr3:71,770,084 T > C, chr3:71,836,145 G
> A, chr3:71,917,591 C > T). These primer sets differed from the sets previously reported [8]. Primer
sequences and annealing temperatures can be found in Supplementary Table S2. Samples were
randomized for genotyping. Polymerase chain reaction (PCR) was performed and verified by gel
electrophoresis, then ExoSap-IT™ PCR Cleanup Reagent (Thermo Fisher Scientific, Waltham, MA,
USA) was used according to manufacturer’s recommendations. Sanger sequencing was performed
and the sequences were analyzed using Sequencher (Gene Codes Corporation, Ann Arbor, MI, USA).
A Fisher’s Exact Test was performed for each SNP using both allelic counts and genotypic counts
and significance was evaluated using both an uncorrected (P < 0.05) and Bonferroni-corrected (P
< 0.012) P value. The Functional Annotation of the Animal Genome (FAANG) alignment files for
Equcab2.0 were viewed using Integrative Genome Viewer (IGV) [10] to analyze ADGRL3 expression in
the frontal lobe, occipital lobe, parietal lobe, cerebellum, lumbar spinal cord, and dorsal root ganglia.
SNP positions were converted to EquCab3.0 using the NCBI remap tool (https://www.ncbi.nlm.nih.
gov/genome/tools/remap) for comparison.
3. Results
Individual horse genotypes for each SNP are provided in Supplementary Table S1. For SNP 1
(chr3:71,768,217 T > A), only two homozygous alternate individuals were found in the study population,
one case and one control. Seven cases and 13 controls were heterozygous, and the remaining 23 cases
and 29 controls were homozygous for the reference allele (allelic P = 0.66) (Figure 1). Similar to SNP
1, only two homozygous alternate individuals were found for SNP 2 (chr3:71,770,084 T > C), along
with seven heterozygous cases and 12 heterozygous controls (allelic P = 0.82) (Figure 1). For SNP 3
(chr3:71,836,145 G > A), 10 cases and 15 controls were homozygous for the alternate allele, with nine
cases and 16 controls being homozygous for the reference allele and 12 cases and controls being
heterozygous (allelic P = 0.87) (Figure 1). Finally, genotyping of SNP 4 (chr3:71,917,591 C > T) identified
19 cases and 26 controls as homozygous for the alternate genotype. Only 12 cases and 17 controls
contained the reference allele (allelic P = 0.85) (Figure 1). There was no significant difference (P > 0.05)
in proportion of homozygous reference genotype, homozygous alternate genotype, and heterozygous
individuals between cases and controls across the four SNPs (Figure 1). A Fisher’s Exact Test was also
performed to compare genotypes since a recessive mode of inheritance has been suggested [8], resulted
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in P = 1.00 for all SNPs assuming a recessive mode of inheritance, demonstrating no association
between the homozygous recessive genotype and eNAD/EDM cases. Remapping of SNP positions to
EquCab3.0 (Supplementary Table S3) revealed a change in the reference allele for the chr3:71,836,145
SNP. The new reference was A and the alternate G at EquCab3.0 chr3:73,700,220.
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4. Discussion
These data collected in this study fail to support an association between the four previously
identified SNPs in ADGRL3 and eNAD/ED cases. It should also be noted that the two controls
in the previous study were half-siblings and therefore relatedness could be the cause of associated
genotype findings [8]; a concern that has been raised previously [11]. ithin our study, there ere
no closely related individuals. As there ere no Caspian horses in the current study sa ple, e are
unable to dra conclusions regarding the Caspian breed. o ever, the Caspian breed is closely
related to the Middle Eastern breeds, such as Arabian and Akhal Teke [12]. Though located on different
branches of an unrooted neighbor joining tree, the Middle Eastern breeds are also related to the
Iberian breeds, which include Andalusian and Lusitano [12]. Our study included one Arabian, one
Lusitano, one Lusitano cross, and three Andalusians that were affected, as well as one Arabian and
two Lusitanos that were unaffected (Supplementary Table S1). All affected and unaffected Arabians,
Andalusians, and Lusitanos were the homozygote reference genotype for SNP 1 (chr3:71,768,217
T > A) and SNP 2 (chr3:71,770,084 T > C) (Supplementary Table S1). For SNP 3 (chr3:71,836,145
G > A), affected and unaffected Arabian and Lusitano horses were either the homozygote reference or
heterozygote genotype (Supplementary Table S1). The affected and unaffected Lusitano horses were
the homozygote alternate genotype or the heterozygote genotype for SNP 4 (chr3:71917591 C > T)
(Supplementary Table S1). Therefore, the four variants were determined to be not associated ith
eNAD/EDM, even within the Arabian and Lusitano breeds. Additionally, as the alternate alleles for
each SNP were identified across many breeds, these variants are unlikely to have a detrimental effect.
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Although expressed in the central nervous system, ADGRL3 is not a strong candidate gene
for eNAD/EDM. Equine NAD/EDM is associated with a postnatal vitamin E deficiency and most
closely resembles ataxia with vitamin E deficiency in humans, an inherited disorder with mutations
in tocopherol transfer protein (TTPA) [5]. The current literature does not support a role for ADGRL3
in vitamin E absorption, transport, or metabolism. Moreover, ADGRL3 is not expressed in intestinal
or hepatic tissue (https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADGRL3). Instead, ADGRL3
genetic variants have been associated with attention-deficit/hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD) susceptibilities [13,14]. ADGRL3 is highly expressed in human fetal brain and
spinal cord (https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADGRL3) and horses demonstrate a
similar pattern of gene expression throughout the frontal lobe, occipital lobe, parietal lobe, cerebellum,
lumbar spinal cord, and dorsal root ganglia [15] (https://www.ebi.ac.uk/ena/data/view/ERA148755).
However, in horses with eNAD/EDM, axonal swellings, termed spheroids, occur in the brainstem and
spinal cord [4]. There has been no association, in any species, with genetic ADGRL3 variants leading to
axonal loss.
In conclusion, we have demonstrated no genetic association between previously identified
genetic variants in ADGRL3 and eNAD/EDM across many breeds of horses. As this population
of horses was stringently phenotyped using postmortem-confirmed cases and a large number of
postmortem-confirmed controls, and the alternate allele for these variants was found in many breeds,
these variants should not be used when diagnosing ataxic horses for eNAD/EDM or to inform
breeding decisions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/9/681/s1,
Table S1: All individuals included in the current study with their disease status, respective age (at euthanasia
or exam), sex, breed, and genotype at each SNP. Table S2: Primers and annealing temperatures for each SNP
genotyped. Table S3: SNP positions in EquCab2.0 compared to EquCab3.0.
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